End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.53 CNY | -0.23% | -0.74% | -14.57% |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 56% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.57% | 1.41B | - | ||
+42.69% | 750B | C+ | ||
+34.11% | 606B | B | ||
-6.87% | 356B | C+ | ||
+18.74% | 326B | B- | ||
+6.76% | 286B | C+ | ||
+18.08% | 246B | B+ | ||
-3.44% | 213B | A+ | ||
+11.35% | 213B | B- | ||
+2.64% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600557 Stock
- Ratings Jiangsu Kanion Pharmaceutical Co.,Ltd.